peptide yy

Peptide YY (PYY) is a 36-amino acid peptide and anorectic gut hormone agonist for the neuropeptide Y receptors Y1, Y2, Y5, and Y6 with EC50 values of 0.7, 0.58, 1, and 0.8 nM, respectively, for supression of forskolin-induced cAMP accumulation. PYY is cleaved in vivo to PYY (3-36) . Release of PYY occurs postprandially in proportion to calorie intake from intestinal enteroendocrine L cells, indicating it may be a satiety signal. In humans, PYY inhibits food intake and gastrointestinal transit in both lean and obese subjects.

Peptide YY (PYY) (3-36), human (TFA) is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite[1].

Peptide YY (PYY) (3-36), human (Peptide YY (3-36)), is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite.

Peptide YY (PYY) (3-36), human trifluoroacetate is a useful organic compound for research related to life sciences and the catalog number is T64716.

Peptide YY (PYY) (3-36), porcine TFA, acts as a gut hormone and Y2 receptor agonist, effectively reducing appetite [1].

Peptide YY (pig), a 36-amino acid gastrointestinal peptide isolated from porcine duodenum, suppresses appetite and reduces food intake through activation of the Y2 receptor. Predominantly located in pancreatic endocrine cells, it influences intestinal motility and impacts the cardiovascular system [1] [2] [3].

(Pro34)-Peptide YY (human) is a highly Y1-selective full agonist of Peptide YY/neuropeptide Y receptors [1].

(Leu31,Pro34)-Peptide YY (human) is a derivative of Peptide YY that acts as a potent and selective Y1 receptor agonist, with a dissociation constant (KD) of 1.0 nM [1].

Peptide YY (13-36) (canine, mouse, porcine, rat) is a Y2 receptor subtype agonist [1].

"(Leu31,Pro34)-Peptide YY (human) (TFA) is the trifluoroacetic acid (TFA) form of (Leu31,Pro34)-Peptide YY (human), a derivative of Peptide YY that acts as a potent and selective Y1 agonist, exhibiting a dissociation constant (K D) of 1.0 nM [1]."

Peptide YY (PYY), a novel 36 amino-acid amidated hormone is a component of the complex neuroendocrine control process.Peptide YY (PYY) can mediate its effects through the Neuropeptide Y receptors.

Peptide YY (PYY) (3-36), human acetate (126339-09-1 Free base) is a NPY (neuropeptide Y) Y2 receptor agonist that suppresses intestinal fluid secretion and slows colonic transit to inhibit diarrhea in mice.

FR252384 is an antagonist of the neuropeptide Y-Y5 receptor (IC50: 2.3 nM).

Dirlotapide (CP742033) is an intestinal selective microsomal triglyceride transfer protein (MTP) inhibitor. It reduces body weight in diabetic dogs.Dirlotapide reduces food intake in a dose-dependent manner, possibly by increasing the release of peptide YY into the circulation.

JNJ-5207787 is a blood–brain barrier penetrant neuropeptide Y Y2 receptor antagonist that demonstrates greater than 100-fold selectivity over Y1, Y4, and Y5 receptor subtypes, JNJ-5207787 potently suppresses peptide YY binding at both human and rat Y2 receptors, supporting the use of JNJ-5207787 in central nervous system research focused on neuropeptide signaling.

FFA2 agonist-1 (Compound 4) is an agonist of the free fatty acid receptor 2 (FFA2/GPR43) with an EC50 of 81 nM. It demonstrates activity in β-arrestin-2 recruitment and cAMP inhibition assays, with EC50 values of 1.2 μM and 0.53 μM, respectively. FFA2 agonist-1 can induce the mucosal response of appetite-regulating peptide YY (PYY), inhibit fat accumulation, and affect intestinal function and food intake, making it useful for obesity research.

Positive allosteric modulator of neuropeptide Y receptor 4 (Y4R). Potentiates Y4R response to pancreatic polypeptide (PP), neuropeptide Y (NPY) and peptide YY (PYY) (EC50 values are 0.03, 0.4 and 0.5 nM respectively). Shows selectivity for Y4R over Y1R, Y2R and Y5R. Schubert et al (2017) Identification and characterization of the first selective Y4 receptor positive allosteric modulator. J.Med.Chem. 60 7605 PMID:28795803

NNC0165-1273 is a peptide YY (PYY3-36) analogue acting as an intestinal hormone. It shows significantly higher affinity for the Y2 receptor compared to the Y1, Y4, and Y5 receptors. NNC0165-1273 effectively induces anorexia and decreases food intake prompted by nocturnal and ghrelin stimulation through increased satiety. It also inhibits the expression of cFos in NPY/AgRP neurons induced by ghrelin. NNC0165-1273 is applicable in anti-obesity therapy research.